PMC:6218602 / 66110-67615 JSONTXT

{"project":"2_test","denotations":[{"id":"30425662-27113497-41865533","span":{"begin":1500,"end":1503},"obj":"27113497"}],"text":"The principal investigator, Dr. Iluminada Corripio has recently reported positive findings in the first subject who participated in this clinical trial. The patient had a long history of ultra-resistant schizophrenia-positive symptom domain refractory symptoms including manifestations of persecutory, control and delusions of reference. Her referential delusions had become so pronounced that she was unable to leave her home. The patient had a long treatment history typical of ultra-resistant schizophrenia including many trials with a number of different antipsychotic medications, including the use of clozapine (600 mg/day) with little benefit. The patient underwent bilateral electrode implantation in the nucleus accumbens and left-sided unilateral stimulation. Improvement was achieved in both positive and negative symptoms measured 4 weeks post-implantation and after 11 months of open treatment, the patient experienced over a 60% reduction in positive symptoms as measured by the positive symptoms subscale of the PANSS as well as a 33% reduction in negative symptoms, 50% reduction in the PANSS disorganization factor, 33% reduction in PANSS excited factor and 16.7% increase in the depressed factor. The patient continues to do well and is now able to leave her home and has made significant improvements to her overall functioning. For this patient with ultra-resistant schizophrenia, this DBS treatment option was of substantial benefit to otherwise untreatable refractory symptoms (207)."}